SPOTLIGHT: Inhibitex raising $41M

Inhibitex plans to raise $41 million through a private placement of 5 million shares. The money will go to develop Veronate, further advance its Aurexis clinical program and fund the company's preclinical and research programs. Release

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.